<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE311nnn/GSE311215/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311215</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Transcriptomic profiling in estrogen receptor-positive breast cancer cell lines CAMA-1 and ZR-75-1 following CDK4/6 inhibitor treatment</name><description>The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens. How pharmacologically activated Rb remodels chromatin and influences transcription beyond cell cycle arrest remains poorly understood. Here we show that CDK4/6 inhibition induces redistribution of hypo-phosphorylated Rb to promoters and enhancers. While Rb predictably binds to cell cycle gene promoters to repress transcription, at other sites it unexpectedly promotes expression of oestrogen-responsive genes by integrating into oestrogen receptor (ER)-rich transcriptional hubs. CDK4/6 inhibition enhances ER target gene expression in breast cancer cells, patient-derived xenografts, and clinical HR+ breast cancer samples in an Rb-dependent manner. This reprogramming is mediated in part by KDM5A, whose interaction with Rb contributes to gene regulation at these loci. Critically, components of this Rb-driven ER transcriptional program are pro-proliferative. In endocrine-sensitive tumours, this can be neutralised with anti-oestrogen therapy, explaining therapeutic synergy. In endocrine-resistant settings such as ESR1-mutant breast cancer, the program persists, limiting therapeutic efficacy. These findings reframe Rb as a dual-function transcriptional regulator that, while enforcing cell cycle arrest, can also activate programs that counteract its tumour suppressor function.</description><dates><publication>2026/06/29</publication></dates><accession>GSE311215</accession><cross_references><GSM>GSM9321208</GSM><GSM>GSM9321209</GSM><GSM>GSM9321202</GSM><GSM>GSM9321203</GSM><GSM>GSM9321211</GSM><GSM>GSM9321200</GSM><GSM>GSM9321201</GSM><GSM>GSM9321206</GSM><GSM>GSM9321207</GSM><GSM>GSM9321204</GSM><GSM>GSM9321205</GSM><GSM>GSM9321194</GSM><GSM>GSM9321195</GSM><GSM>GSM9321198</GSM><GSM>GSM9321199</GSM><GSM>GSM9321210</GSM><GSM>GSM9321196</GSM><GSM>GSM9321197</GSM><GPL>18573</GPL><GSE>311215</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>